CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briles, D. E.
Right arrow Articles by McDaniel, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briles, D. E.
Right arrow Articles by McDaniel, L. S.

 Previous Article

Clinical Microbiology Reviews, October 1998, p. 645-657, Vol. 11, No. 4
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Pneumococcal Diversity: Considerations for New Vaccine Strategies with Emphasis on Pneumococcal Surface Protein A (PspA)

David E. Briles,1,2,3,* Rebecca Creech Tart,1 Edwin Swiatlo,1 Joseph P. Dillard,1 Patricia Smith,1 Kimberly A. Benton,1 Beth A. Ralph,1 Alexis Brooks-Walter,1 Marilyn J. Crain,1,2 Susan K. Hollingshead,1 and Larry S. McDaniel1

Departments of Microbiology,1 Pediatrics,2 and Comparative Medicine,3 University of Alabama at Birmingham, Birmingham, Alabama

Streptococcus pneumoniae is a problematic infectious agent, whose seriousness to human health has been underscored by the recent rise in the frequency of isolation of multidrug-resistant strains. Pneumococcal pneumonia in the elderly is common and often fatal. Young children in the developing world are at significant risk for fatal pneumococcal respiratory disease, while in the developed world otitis media in children results in substantial economic costs. Immunocompromised patients are extremely susceptible to pneumococcal infection. With 90 different capsular types thus far described, the diversity of pneumococci contributes to the challenges of preventing and treating S. pneumoniae infections. The current capsular polysaccharide vaccine is not recommended for use in children younger than 2 years and is not fully effective in the elderly. Therefore, innovative vaccine strategies to protect against this agent are needed. Given the immunogenic nature of S. pneumoniae proteins, these molecules are being investigated as potential vaccine candidates. Pneumococcal surface protein A (PspA) has been evaluated for its ability to elicit protection against S. pneumoniae infection in mouse models of systemic and local disease. This review focuses on immune system responsiveness to PspA and the ability of PspA to elicit cross-protection against heterologous strains. These parameters will be critical to the design of broadly protective pneumococcal vaccines.

* Corresponding author. Mailing address: Department of Microbiology, University of Alabama at Birmingham, 658 BBRB, Mail Box 10, Birmingham, AL 35294-2170. Phone: (205) 934-6595. Fax: (205) 934-0605. E-mail: david_briles{at}micro.microbio.uab.edu.

Clinical Microbiology Reviews, October 1998, p. 645-657, Vol. 11, No. 4
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.